Mike Aperghis

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

John V. Heymach, David H. Harpole, Tetsuya Mitsudomi et al. · New England Journal of Medicine · 2023 · 682 citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial

John V. Heymach, Tetsuya Mitsudomi, David H. Harpole et al. · Clinical Lung Cancer · 2021 · 109 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

John V. Heymach, David H. Harpole, Tetsuya Mitsudomi et al. · Cancer Research · 2023 · 84 citations

Medicine, Oncology, Pharmacotherapy +17

P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

John V. Heymach, Janis M. Taube, Tetsuya Mitsudomi et al. · Journal of Thoracic Oncology · 2019 · 22 citations · Full text

Medicine, Oncology, Chemotherapy +11

OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial

John V. Heymach, David Harpole, T. Mitsudomi et al. · Journal of Thoracic Oncology · 2024 · 20 citations · Full text

Medicine, Oncology, Surgery +5